Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: NASDAQ GS
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

EXEL:US

3.0900 USD 0.1600 5.46%

As of 20:10:00 ET on 03/02/2015.

Snapshot for Exelixis Inc (EXEL)

Open: 2.9700 Day's Range: 2.9300 - 3.1000 Volume: 4,471,690
Previous Close: 2.9300 52wk Range: 1.2600 - 7.5800 1-Yr Rtn: -56.90%

Stock Chart for EXEL

No chart data available.
  • EXEL:US 3.0900
  • 1D
  • 1M
  • 1Y
2.9300
Interactive EXEL Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for EXEL

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) -
Relative P/E vs. SPX -
Earnings Per Share (USD) (ttm) -1.3462
Est. EPS (USD) (12/2015) -0.8600
Est. PEG Ratio -
Market Cap (M USD) 605.32
Shares Outstanding (M) 195.90
30 Day Average Volume 4,745,163
Price/Book (mrq) -
Price/Sale (ttm) 23.9358
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 05/01/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for EXEL

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for EXEL

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of small-molecule therapeutics for the treatment of cancer and other serious diseases. The Company is building a portfolio of compounds it believes could become pharmaceutical products. Exelixis has strategic alliances with pharmaceutical and biotechnology companies.

Michael M MorrisseyPresident/CEOJeffrey J HessekielExec VP/General Counsel
Gisela M SchwabExec VP/Chief Medical OfficerPamela A SimontonExec VP
More Company Profile & Key Executives for EXEL

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil